Since the main aim of this research is to explore circulating biomarkers that would predict the onset of breast cancer, the expression levels of miRNAs-145, -382, and -21 panel were assessed using qRT-PCR, besides HER2/neu by ELISA, as well as metabolomics (amino acids profiling) by LC/MS/MS in the blood samples of healthy, benign, and breast cancer candidates. This evidence concerns the gene ERBB2 and breast carcinoma.